Ascendis Pharma A (ASND) Total Current Liabilities (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Total Current Liabilities data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 41.62% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 41.62% YoY), and the FY2025 full-year result was $1.2 billion, up 55.65% from the prior year.
• Total Current Liabilities rose to $1.3 billion in Q1 2026, from $1.2 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.3 billion in Q1 2026 to a low of $107.0 million in Q1 2022.
• A 5-year average of $658.4 million and a median of $792.4 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 353.5% in 2023 and decreased 0.36% in 2024, its largest moves.
• Tracing ASND's Total Current Liabilities over 5 years: stood at $174.7 million in 2022, then jumped by 353.5% to $792.4 million in 2023, then declined by 0.36% to $789.6 million in 2024, then surged by 57.65% to $1.2 billion in 2025, then advanced by 5.97% to $1.3 billion in 2026.
• Business Quant data shows ASND's Total Current Liabilities at $1.3 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.2 billion in Q3 2025.